Apr 25, 2026
Apr 25, 2026
Apr 25, 2026
Apr 25, 2026
Apr 25, 2026
Apr 25, 2026
Apr 25, 2026
Apr 25, 2026
Julie Rubinstein, President of Adaptive Biotechnologies, sold over 57,000 shares recently, raising questions about company prospects. What does this move signal for investors and the biotech market?